Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company focused on the discovery, development and commercialization of innovative proprietary therapeutics, today announced it has been ranked 7th on Forbes magazine’s 2015 list of the World’s Most Innovative Companies.

Forbes’ ranking is based on the companies’ “innovation premium”, and only includes industries that are known to invest in innovation and businesses that have at least seven years of financial data and a market value greater than $10 billion.

“To be included in Forbes’ World’s Most Innovative Companies list is an honor for our company and our employees,” said Hervé Hoppenot, President and Chief Executive Officer of Incyte. “This recognition underscores the passion and pride we at Incyte demonstrate every day, as we work to advance innovative science and identify new molecules that will deliver on our goal of improving the lives of patients with cancer.”

To view the complete list, visit http://www.forbes.com/innovative-companies/.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Company’s website at www.incyte.com.